Arkea Bio
About Arkea Bio
Arkea Bio develops a vaccine that reduces methane emissions from ruminant livestock by neutralizing methane-producing microbes in the rumen, thereby decreasing greenhouse gas output from the agricultural sector. This technology addresses the significant contribution of livestock methane emissions, which account for over 3 billion tonnes of CO2 equivalents annually, by enabling more sustainable meat and dairy production.
```xml <problem> Ruminant livestock, such as cattle, produce significant methane emissions, contributing over 3 billion tonnes of CO2 equivalents annually to greenhouse gas emissions. These emissions, primarily from the methanogens in the rumen, have a disproportionately high global warming potential compared to carbon dioxide. Current strategies to mitigate these emissions are often costly, difficult to scale, or disruptive to existing agricultural practices. </problem> <solution> ArkeaBio is developing a vaccine that reduces methane emissions from ruminant livestock by targeting and neutralizing methane-producing microbes (methanogens) within the rumen. The vaccine stimulates the animal's immune system to produce antibodies that are delivered to the rumen via saliva. These antibodies bind to methanogens, reducing their population and, consequently, the amount of methane produced during digestion. By reducing methane production, the vaccine also allows the animal to retain more energy from its feed, potentially improving feed efficiency. The vaccine is designed to integrate seamlessly into existing livestock management practices, offering a scalable and cost-effective solution for decarbonizing meat and dairy production. </solution> <features> - Vaccine-induced antibody production targeting key methanogens in the rumen - Reduction of methane production in the rumen, leading to lower greenhouse gas emissions - Improved feed efficiency as a result of reduced methane-related energy loss - Compatibility with existing livestock vaccination protocols and administration methods - Continuous target refinement based on microbiome analysis to maintain efficacy against evolving methanogen populations - Scalable manufacturing and distribution to reach a global cattle population - Designed for safety with no impact on meat or milk quality </features> <target_audience> The primary target audience includes farmers, ranchers, and other livestock producers seeking to reduce the environmental impact of their operations, as well as food producers and governments aiming to meet sustainability targets and reduce the carbon footprint of the agricultural sector. </target_audience> ```
What does Arkea Bio do?
Arkea Bio develops a vaccine that reduces methane emissions from ruminant livestock by neutralizing methane-producing microbes in the rumen, thereby decreasing greenhouse gas output from the agricultural sector. This technology addresses the significant contribution of livestock methane emissions, which account for over 3 billion tonnes of CO2 equivalents annually, by enabling more sustainable meat and dairy production.
Where is Arkea Bio located?
Arkea Bio is based in Charlestown, Australia.
When was Arkea Bio founded?
Arkea Bio was founded in 2022.
How much funding has Arkea Bio raised?
Arkea Bio has raised 38500000.
- Location
- Charlestown, Australia
- Founded
- 2022
- Funding
- 38500000
- Employees
- 28 employees
- Major Investors
- Breakthrough Energy Ventures